<DOC>
	<DOCNO>NCT01271504</DOCNO>
	<brief_summary>The purpose study determine whether patient hepatocellular carcinoma receive either E7050 administer Sorafenib Sorafenib alone experience great benefit ( cancer respond treatment ) E7050 administer Sorafenib .</brief_summary>
	<brief_title>E7050 Combination With Sorafenib Versus Sorafenib Alone First Line Therapy Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>This open-label , multicenter , randomize study consist Phase Ib : safety run-in period 3 ascending dos E7050 combination sorafenib ; Phase II portion : randomize 2-arm period . Approximately 95 patient hepatocellular carcinoma enrol study ( 10-15 patient Phase Ib portion 80 patient Phase II portion ) . Patients participate either Phase Ib Phase II portion study . In Phase Ib phase II , Patients receive study treatment ( E7050 plus sorafenib sorafenib alone ) occurrence progressive disease ( PD ) approximately six 28-day cycle ( 24 week ) . After 6 cycle . ath discretion Investigator consultation Medical Monitor , patient experience clinical benefit may continue E7050 , without sorafenib ( Arm 1 ) , may continue sorafenib alone ( Arm 2 ) , depend original randomization treatment arm , long clinical benefit sustain treatment well tolerate . Patients follow death follow completion therapy .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria Unresectable locally advance metastatic HCC ; Histologic confirmation require diagnostic criterion meet ; No previous systemic anticancer therapy permit ( 2 prior systemic anticancer regimen allow Phase Ib ) . Previous chemoembolization , radioembolization , radiofrequency ablation , local ablative therapy permit great 6 week first day studydefined treatment ; ECOG PS 0 1 ; ChildPugh Cirrhotic Status A B score 7 ; Blood pressure must wellcontrolled ( less equal 140/90 mmHg screening ) without antihypertensive medication . Patients must history hypertensive crisis hypertensive encephalopathy ; Exclusion Criteria Previously receive E7050 anticmet , antiangiogenic therapy ( prior antiangiogenic therapy permit Phase Ib ) ; Presence brain metastasis , unless patient received adequate treatment least 4 week prior randomization , stable , asymptomatic , steroid least 4 week prior randomization ; Palliative radiotherapy permit throughout study period ; Active hemoptysis Serious nonhealing wound , ulcer , active bone fracture ; Major surgical procedure , open biopsy significant traumatic injury within 28 day prior commence study treatment , anticipation need major surgical procedure course study ; Clinically significant gastrointestinal bleeding ( bleed require procedural intervention , eg . variceal banding , transjugular intrahepatic portosystemic shunt ( TIPS ) procedure , arterial embolization , topical coagulation therapy ) within 6 month prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>liver</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>phase I</keyword>
	<keyword>phase II</keyword>
</DOC>